发明名称 Peptidomimetic protease inhibitors
摘要 The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
申请公布号 US8252923(B2) 申请公布日期 2012.08.28
申请号 US20080231982 申请日期 2008.09.08
申请人 BABINE ROBERT EDWARD;CHEN SHU-HUI;LAMAR JASON ERIC;SNYDER NANCY JUNE;SUN XICHENG;TEBBE MARK JOSEPH;VICTOR FRANTZ;WANG Q. MAY;YIP YVONNE YEE MAI;COLLADO IVAN;GARCIA-PAREDES CRISTINA;PARKER, III RAYMOND SAMUEL;JIN LING;GUO DEQI;GLASS JOHN IRVIN;VERTEX PHARMACEUTICALS INCORPORATED 发明人 BABINE ROBERT EDWARD;CHEN SHU-HUI;LAMAR JASON ERIC;SNYDER NANCY JUNE;SUN XICHENG;TEBBE MARK JOSEPH;VICTOR FRANTZ;WANG Q. MAY;YIP YVONNE YEE MAI;COLLADO IVAN;GARCIA-PAREDES CRISTINA;PARKER, III RAYMOND SAMUEL;JIN LING;GUO DEQI;GLASS JOHN IRVIN
分类号 C07D265/34;C12N9/99;A61K;A61K31/13;A61K31/437;A61K31/7052;A61K31/713;A61K38/00;A61K38/04;A61K38/05;A61K38/21;A61K38/55;A61K45/00;A61P;A61P1/16;A61P31/14;A61P43/00;C07C229/00;C07D207/08;C07D209/02;C07D209/52;C07D233/32;C07D241/08;C07D275/06;C07D403/02;C07D417/02;C07D493/14;C07K;C07K5/02;C07K5/023;C07K5/027;C07K5/03;C07K5/04;C07K5/06;C07K7/02;C07K7/06;C07K14/18;C12N7/06 主分类号 C07D265/34
代理机构 代理人
主权项
地址